Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 486 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Working Mom with Stage II Breast Cancer Receives Custom Wig Made... July 30, 2020 What is De-escalation Treatment in Cancer Research? May 30, 2023 Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’... December 12, 2021 More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease May 29, 2020 Load more HOT NEWS A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... Teacher Visits Student Battling Cancer At Home To Help With His... Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... November is National Family Caregivers Month
